Abstract
Even though much progress has been made towards understanding the molecular nature of glioma, the survival rates of patients affected by this tumour have not changed significantly over recent years. Better knowledge of this malignancy is still needed in order to predict its outcome and improve patient treatment. VAV1 is an GDP/GTP exchange factor for Rho/Rac proteins with oncogenic potential that is involved in the regulation of cytoskeletal dynamics and cell migration. Here we report its overexpression in 59 patients diagnosed with high-grade glioma, and the associated upregulation of a number of genes coding for proteins also involved in cell invasion- and migration-related processes. Unexpectedly, immunohistochemical experiments revealed that VAV1 is not expressed in glioma cells. Instead, VAV1 is found in non-tumoural astrocyte-like cells that are located either peritumouraly or perivascularly. We propose that the expression of VAV1 is linked to synergistic signalling cross-talk between cancer and infiltrating cells. Interestingly, we show that the pattern of expression of VAV1 could have a role in the neoplastic process in glioblastoma tumours.
- Content Type Journal Article
- Category Clinical Study - Patient Study
- Pages 1-9
- DOI 10.1007/s11060-012-0936-y
- Authors
- Juan Luis Garcia, Research Unit, IECSCYL-Hospital Universitario de Salamanca. IBSAL, IBMCC (USALCSIC), Paseo San Vicente 58, 37007 Salamanca, Spain
- Jose Couceiro, Centro de Investigación del Cáncer and Instituto de Biología Molecular y Celular del Cáncer, Universidad de Salamanca-CSIC, Salamanca, Spain
- Juan Antonio Gomez-Moreta, Neurosurgery Service, Hospital Universitario de Salamanca, Salamanca, Spain
- J. M. Gonzalez Valero, Research Unit, IECSCYL-Hospital Universitario de Salamanca, Paseo San Vicente 58, 37007 Salamanca, Spain
- Angel Santos Briz, Department of Pathology, Hospital Universitario de Salamanca, Salamanca, Spain
- Vincent Sauzeau, Centro de Investigación del Cáncer and Instituto de Biología Molecular y Celular del Cáncer, Universidad de Salamanca-CSIC, Salamanca, Spain
- Eva Lumbreras, Centro de Investigación del Cáncer and Instituto de Biología Molecular y Celular del Cáncer, Universidad de Salamanca-CSIC, Salamanca, Spain
- Manuel Delgado, Centro de Investigación del Cáncer and Instituto de Biología Molecular y Celular del Cáncer, Universidad de Salamanca-CSIC, Salamanca, Spain
- Cristina Robledo, Centro de Investigación del Cáncer and Instituto de Biología Molecular y Celular del Cáncer, Universidad de Salamanca-CSIC, Salamanca, Spain
- Monica Lara Almunia, Neurosurgery Service, Hospital Universitario de Salamanca, Salamanca, Spain
- Xose R. Bustelo, Centro de Investigación del Cáncer and Instituto de Biología Molecular y Celular del Cáncer, Universidad de Salamanca-CSIC, Salamanca, Spain
- Jesus M. Hernandez, Centro de Investigación del Cáncer and Instituto de Biología Molecular y Celular del Cáncer IBSAL, IBMCC (USALCSIC) Department of Haematology, Hospital Universitario de Salamanca, Paseo San Vicente 58, 37007 Salamanca, Spain
- Journal Journal of Neuro-Oncology
- Online ISSN 1573-7373
- Print ISSN 0167-594X
Sent with MobileRSS HD FREE
No comments:
Post a Comment